[Agomelatine in real-life condition: A safe context of prescription? Results of a one-year single-center evaluation]

Therapie. 2018 May-Jun;73(3):299-301. doi: 10.1016/j.therap.2017.10.008. Epub 2017 Nov 24.

[Article in French]

Authors

Hervé Javelot¹, Marie Berard², Delphine Grégoire², Cathy Nonnenmacher²

Affiliations

¹ Service pharmacie, établissement public de santé Alsace-Nord, 67170 Brumath, France. Electronic address: herve.javelot@ch-epsan.fr.
² Service pharmacie, établissement public de santé Alsace-Nord, 67170 Brumath, France.

PMID: 29246378
DOI: 10.1016/j.therap.2017.10.008

No abstract available

Keywords: Agomelatine; Agomélatine; Clinical safety; Follow-up of liver function; Suivi de la fonction hépatique; Sécurité clinique.

Publication types

Letter

MeSH terms

Acetamides / adverse effects*
Acetamides / therapeutic use*
Adolescent
Adult
Aged
Aged, 80 and over
Antidepressive Agents / adverse effects*
Antidepressive Agents / therapeutic use*
Chemical and Drug Induced Liver Injury / metabolism
Depressive Disorder, Major
Female
Humans
Male
Middle Aged
Patient Safety
Prescriptions
Retrospective Studies
Risk
Young Adult

Substances

Acetamides
Antidepressive Agents
agomelatine